Leap Therapeutics, Inc. (LPTX)

Market Cap	71.33M
Revenue (ttm)	n/a
Net Income (ttm)	-81.05M
Shares Out	25.57M
EPS (ttm)	-5.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	266,714
Open	2.67
Previous Close	2.72
Day's Range	2.65 - 2.93
52-Week Range	1.24 - 10.20
Beta	0.66
Analysts	Strong Buy
Price Target	14.13 (+406.45%)
Earnings Date	Nov 13, 2023

About LPTX

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, I...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: LPTX

Analyst Forecast

According to 4 analysts, the average rating for LPTX stock is "Strong Buy." The 12-month stock price forecast is $14.13, which is an increase of 406.45% from the latest price.

Price Target

$14.13

(406.45% upside)

Analyst Consensus: Strong Buy